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Abstract: Invasive meningococcal disease (IMD) is a major public health concern because
of its high case fatality, long-term morbidity, and potential to course with outbreaks. IMD
caused by Nesseira meningitidis serogroup B has been predominant in different regions of
the world like Europe and only recently broadly protective vaccines against B serogroup
have become available. Two protein-based vaccines, namely 4CMenB (Bexsero®) and
rLP2086 (Trumenba®) are currently licensed for use in different countries against MenB
disease. These vaccines came from a novel technology on vaccine design (or antigen
selection) using highly specific antigen targets identified through whole-genome sequence
analysis. Moreover, it has the potential to confer protection against non-B meningococcus
and against other Neisserial species such as gonococcus. Real-world data on the vaccine-use
are rapidly accumulating from the UK and other countries which used the vaccine for control
of outbreak or as part of routine immunization program, reiterating its safety and efficacy.
Additional data on real-life effectiveness, long-term immunity, and eventual herd effects,
including estimates on vaccine impact for cost-effectiveness assessment are further needed.
Given the predominance of MenB in Europe and other parts of the world, these new vaccines
are crucial for the prevention and public health control of the disease, and should be
considered.
Keywords: meningococcal disease, invasive meningococcal disease, meningococcal B,
vaccine development, vaccine effectiveness, epidemiology
Introduction
Etiology
Neisseria meningitidis (meningococcus) is a gram-negative encapsulated bacteria
which causes invasive meningococcal disease (IMD). The most frequent clinical
presentations are meningitis and septicemia, both of which are responsible for
significant morbidity and mortality worldwide.1–3 Humans are the only host for
the bacteria. Meningococcus is also a common commensal in the nasopharynx,
transmitted from person-to-person via respiratory secretions.1 Nasopharyngeal car-
riage prevalence varies with age, having its peak (23.7%) in adolescents and young
adults. It may also be substantially higher (up to 71%) in closed communities like
college residences and military camps.4–6
The most common pathogenic groups in humans are A, B, C, W, X, and Y,
which can cause endemic disease or seasonal outbreaks.1
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Epidemiology And Burden Of Illness
Invasive meningococcal disease remains a public health
concern worldwide even with safe and effective available
vaccines for use.3,7 More than one million cases are
reported annually.3,7 Case fatality rates range from 10%
to 40% depending mainly on the clinical presentation and
serogroup, despite antibiotic-use and intensive supportive
care.7 Furthermore, survivors may suffer debilitating
sequelae that reduce the quality of life for the patient and
family members.7 Financial burden caused by long-term
morbidities has continuously been underestimated. This is
commonly due to healthcare costs related to permanent
cognitive deficits, psychological stress, and adaptive mea-
sures for reintegration into society.7,8 The holistic analysis
of burden, including both its financial and social aspects,
sums up the real consequences of this debilitating disease.
The incidence of IMD varies with age. The first peak
occurs during the first year of life due to immunological
immaturity, a second peak appears in adolescence related
to an increased carriage, and a third peak in the elderly that
is related to multiple comorbidities.1 In 2017, the average
incidence of IMD across Europe slightly decreased to 0.6
cases per 100,000 population from the 0.7 cases per
100,000 population reported in 2010.3,9 Countries with
the highest number of incidence in 2015 were Lithuania
(2.4 cases/100,000), Ireland (1.5), the Netherlands (1.2),
and the United Kingdom (1.2).3 Despite the low overall
disease incidence, certain serogroups are emerging as a
concern in selected areas.3
The introduction of serogroup C meningococcus10-con-
taining vaccine in the routine immunization across Europe
has resulted in a significant decline in the proportion of
MenC-disease in the region. However, this has minimal to
no effect on other serogroups. N. meningitidis serogroup B
(MenB) has become the leading cause of meningococcal
disease across several regions, including Europe and
America.1,11,12 Although the overall incidence is low com-
pared to other vaccine-preventable diseases, MenB disease
carries substantial case fatality rate at 3% to 10%.12 It also
results in significant morbidity and carries a threat for an
outbreak.13–16 Thus, vaccination against MenB serogroup
has become an important public health priority.
Treatment And Preventive Strategies
Meningococcal disease can be devastating as it is capable
of causing death in a few hours. Antibiotics should be
started as soon as the disease is suspected as their use
aims to reduce the severity and chances of death14
However, the best way to avoid adverse long-term seque-
lae is to prevent infection that could be done through
immunization. Currently available meningococcal conju-
gate vaccines contain polysaccharides from one (A or C),
two (C and Y), or four (A, C, W, and Y) serogroups, which
are chemically conjugated to protein carrier molecules.17
Although conjugated polysaccharide vaccines seem to
work for other serogroups (A, C, Y, W), this has not been
the case for serogroup B. A polysaccharide-based vaccine
was disregarded for two major reasons, its theoretical risk
for autoimmunity and its low immunogenicity. First, there
is similarity of human endogenous glycopeptide with ser-
ogroup B meningococcal capsule.18,19 Although natural
infection is not shown to produce cross-reactive
antibodies,20 the use of polysaccharide capsule to induce
bactericidal antibodies took lesser priority because of its
theoretical risk for auto-antibody responses. Second, the
polysialic acid nature of MenB capsule has been shown to
be poorly immunogenic.21 Initial investigation on the use
of capsular components failed to generate adequate anti-
body responses.22 Likewise, conjugation of the capsular
components failed to show adequate responses on rhesus
monkeys.23 As such, other vaccine targets and vaccine
designs were ventured.
Vaccines Licensed For Use Against
Meningococcus Serogroup B
(MenB)
Currently licensed vaccines, 4CMenB (Bexsero®, GSK)
and rLP2086 (Trumenba®, Pfizer) (see Table 1), used
subcapsular proteins that were widely present not only in
serogroup B strains but also across different meningococ-
cus serogroups.4,24–47 These protein candidates used for
vaccines are summarized in Table 2.
Development Of The 4cMenB Vaccine
The 4CMenB vaccine contains subcapsular protein antigens
intended to induce the production of bactericidal antibodies
against 4 vaccine antigens, namely NHBA, NadA, fHbp, and
Porin A (details summarized in Table 2).48 Multiple subcap-
sular components are thought to enable comprehensive cov-
erage across a number of strains via their respective different
mechanisms of action and thus, also prevent eventual
“escape” strains.19,25
Suitable subcapsular protein targets were first identified
via the process known as “Reverse Vaccinology”. This
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technology used the complete genome sequence of a
pathogenic reference strain of MenB (MC58 strain)49 to
identify proteins suitable for further investigation as vac-
cine candidates.49–52 Of the 2158 genes present in the
complete genome of the reference strain,49 the group
selected 570 that were predicted in-silico to encode for
secreted or surface proteins. Of these, only 350 were
successfully expressed as recombinant proteins, of which
only 28 were found to induce a functional serum bacter-
icidal antibody (SBA) response.48,53 The selection of pro-
teins to be included was based on its ability to induce
bactericidal antibodies, its prevalence across different B
strains, and its capacity to confer protection in an infected
mouse model.53 The three genome-derived Neisseria anti-
gens (GNA) meeting these criteria were Neisserial heparin
binding antigen (NHBA or GNA 2132),52 factor-H bind-
ing protein (fHbp or GNA 1870),54 and Neisseria adhesin
A (NadA or GNA 1994).55 The three proteins, fHbp,
NadA, and NHBA, were observed to have epitopes
which elicit protective antibodies.56 Thus, the practice of
combining different protein targets in a single vaccine will
theoretically result in an enhanced bactericidal response
through synergism. A study has shown that some antibo-
dies directed against fHbp and NHBA may work in a
cooperative manner for their bactericidal effect.57
A mixture of soluble outer membrane vesicles (OMVs)
obtained after detergent extraction was fractionated and
purified, and the resulting formulation was used to immu-
nize mice to identify proteins capable of inducing SBA
against a range of meningococcal strains.26,58
Development Of The rLP2086 Vaccine
An analysis of 2150 strains has shown that fHBP expres-
sion was detected above the limit of detection in >95% of
the investigated isolates, proving the ability to induce a
protective immune response and thus was considered a
reasonable choice for a vaccine antigen.39,58,59 Extensive
molecular epidemiology of MenB clinical isolates col-
lected from European meningococcal reference labora-
tories demonstrated that meningococcal fHBP gene
sequences segregate into two subfamilies, designated A
and B.60 Protein variants within subfamilies share ≥83%
amino acid sequence identity, but only 60–75% identity
between subfamilies.61 The rLP2086 vaccine contains two
lipidated fHbp variants, one from each subfamily A and B,
and aims to broaden cross-protection through a nearly
complete coverage of a single antigen.26 The lipidation
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infection and acts as an adjuvant.62 The selection of fHbp
variants included in rLP2086 vaccine is derived from the
phylogenetic analysis of IMD isolates from the US and
Europe to cover two of the most prevalent variants from
both fHbp subfamilies.59,61,63 The current vaccine formu-
lation contains A05 and B01 variants of the fHbp, with the
addition of aluminium salt as an adjuvant.64
Clinical Studies On Meningococcal
B Vaccines
Due to the low incidence of invasive meningococcal disease
in some countries or the unpredictability of the emergence of
an outbreak, study designs with clinical endpoints are almost
impossible to conduct.65–67 Thus, a correlate of protection is
being used on all meningococcal vaccines in development.
The correlate of protection is an immunologic outcome that
is used as a surrogate measure for efficacy. For serogroups A,
C, W, X, and Y both rabbit (rSBA) and human serum bacter-
icidal assays (hSBA), which measure levels of functional
antibody, are an accepted correlate of protection (although
baby rabbit serum is recommended); whereas human serum
bactericidal assays (hSBA), is the only currently accepted
correlate of protection used for the development of MenB
vaccines.34,68 However, due to the inherent difference of the
two MenB vaccines, each product used a different assay to
measure the correlate of protection and thus, direct compar-
ison of efficacy is not feasible. Tables 3 and 4 summarize the
available data on efficacy and safety of 4CMenB28–30,69–71
and rLP2086,31–33,72 respectively.
Furthermore, the clinical vaccine development program
of the two vaccines was planned for introduction in dif-
ferent age groups, with the 4CMenB for individuals from 2
months of age and older and the rLP2086 for adolescents
from 10 years of age. However, trials have been ongoing
on both vaccines to expand their use among age groups
beyond their current marketing approval.
Immunogenicity Of The 4cMenB Vaccine
4CMenB was shown to elicit good immunogenicity in
infants using 3 doses. Although initial clinical trials were
performed with a total of 4 doses, results from later trials
allowed dose reduction.28,30,69,71,73 Furthermore, concomi-
tant administration of MenC CRM-conjugated vaccine
(MenC-CRM) and 4CMenB in infants was found to be
immunogenic, resulting in a sufficient immune response
against MenB after primary and booster vaccination.38
The immunogenicity of 4CMenB in adolescents was
studied in four clinical studies as part of the clinical vaccine
development program and eventual planned marketing
authorization in the similar age group.35–37,74 hSBA was
assessed against three indicator strains (strain 44/76-SL for
fHbp, strain 5/99 for NadA, and strain NZ98/254 for PorA
P1.4) to determine the immunogenicity of individual vac-
cine components.35,37 A suitable strain for assessing bacter-
icidal activity of NHBA-specific antibodies was not
available at that time, and was later performed using strain
M10713. The primary immunogenicity endpoints in the
four 4CMenB clinical trials were different.35–37,74 The
hSBA titers of ⩾1:4 were used in two studies,37,74,75 but
to ensure a higher assurance of reaching the immunological
endpoint, the subsequent studies have used higher titers as a
cut-off (see Table 3).
In terms of long-term immunogenicity, the primary
course is sufficient to achieve a satisfactory immune
response within 30 days of vaccination for both infants
and adolescents.29,76 A booster dose at 12 months with
4CMenB improved bactericidal responses and facilitated
immune persistence in infants until 28 months of age.29
On the other hand, an additional dose at 40–44 months old
in those who had previously completed the primary course
showed an anamnestic response.77 However, antibody per-
sistence, booster responses, and safety profiles were simi-
lar between vaccination schedules using 2 primary doses
and 3 primary doses.78 Among adolescents, hSBA
declined at 4.5 years and 7 years after primary immuniza-
tion although remained to be higher compared to the
vaccine-naïve population.76,79
Immunogenicity Of The rLP2086 Vaccine
The clinical trials on rLP2086 are peculiar as they used
strains of meningococcus that expressed fHBP variant that
is different from what the vaccine contains (A05 and B01).
This alternative strategy aims to provide an immunologic
proof that the vaccine can induce protective antibodies
against a broader range of meningococcal strains. The
vaccine was then tested for hSBA against the representa-
tive strains of different fHbp type, namely PMB3302
(A04), PMB1256 (B03), PMB2001 (A56), PMB2707
(B44), PMB1321 (A22), and PMB2948 (B24).4,80 A
higher threshold value was also set to ensure high titers
when the vaccine is used in humans (>1:8–16, depending
on the strain).4,81
rLP2086 has shown to elicit robust hSBA responses to
MenB strains expressing different fHBP variants on
Rivero-Calle et al Dovepress
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adolescents at 2 or 3 doses.39 Co-administration with ado-
lescent immunizations and rLP2086 was also evaluated in
some studies. The non-inferiority criteria were met for all
immunogenicity endpoints for MenB strains, MCV4, and
Tdap antigens, as well as for HPV antigens, except
HPV18.82,83 Seroconversion for all 4 HPV antigens was
achieved by ≥99% of subjects in the groups that received
quadrivalent HPV vaccine.83
After three doses of rLP2086, protective hSBA titers
above the correlate of protection (≥1:4) were elicited after
a 4-year follow-up in more than 50% of the children for
the three out of four representative meningococcal strains
expressing the vaccine-heterologous antigens.84 However,
serum titers declined to <1:4 by 9 to 11 months for some
strains, raising concerns by some on the strain-specificity
of the long-term protection.85
Vaccination In Special Groups
The major bactericidal action of antibodies against meningo-
coccus is mediated by the complement system. Thus, chil-
dren with complement deficiencies, asplenia, and splenic
syndromes, and children receiving drugs against the comple-
ment proteins (i.e., eculizumab) are at high-risk for the devel-
opment of invasive meningococcal diseases.86–89 4CMenB is
recommended for children with complement deficiencies,
asplenia, splenic dysfunction, and those receiving the mono-
clonal antibody eculizumab.86 However, data on the safety
and immunogenicity in these patients are scarce.87–89
In a clinical study enrolling children with asplenia or
splenic dysfunction, giving 2 doses of 4CMenB has been
shown to induce bactericidal antibodies as compared to
healthy controls.86 Also, the 4CMenB vaccine was able to
generate bactericidal activity, albeit lower, in the presence of
exogenous complement on the majority of children with
complement deficiency86 The significance of the inferior
responses of SBA titers in complement-deficient children
and those undergoing complement-inhibitor therapy must
be further analyzed and compared with ongoing surveillance
on vaccine failures. Schedules in this subgroups of children
could be revised to accommodate additional dose, the inclu-
sion of a booster, or different dose intervals.86 There is no
data available for special groups with rLP2086 vaccine.
Cross-Protection Against Other
Meningococcal Serogroups
The genes encoding for the antigens fHbp, NHBA, and NadA
can be present and expressed in other serogroups, suggesting a
potential impact of MenB vaccines against non B strains.42
Thus, the vaccine has a theoretical effect against all serogroups
becoming a true universal anti-meningococcal vaccine. The
first investigation was done on the possible cross-protection
against serogroup × causing outbreaks in Africa in a pooled
sera of infants immunized with 4CMenB.43 Although with
small sample size, the sera revealed bactericidal antibodies
against the other serogroup. Further studies have explored the
potential impact of MenB vaccination against non-B menin-
gococcal disease in Australia, Europe, and Brazil.42,44,90 The
results showed that sera of 4CMenB immunized subjects
induced complement-mediated killing of MenC, MenW, and
MenY in a range from 45% to 90%, suggesting that 4CMenB
vaccine could potentially have an impact on non-B meningo-
coccal disease.42–44,90
Immunological responses have been assessed with non-
B meningococcal disease-causing strains from Europe,
Africa, and the United States using rLP2086.39 After 2 or
3 doses of the vaccine, 53% to 100% of individuals had
bactericidal responses against meningococcal serogroup C,
W, Y, and X strains, and 20% to 28% had bactericidal
responses against serogroup A strains.81 In fact, these
bactericidal responses were higher than the serological
correlate of protection for meningococcal disease (hSBA
titers ≥ 1:8 vs hSBA titers ≥ 1:4).91 These results suggest
that rLP2086 could confer protection against meningococ-
cal disease, regardless of serogroup.91
Cross-Protection Against Neisseria
gonorrhoeae (gonococcus)
Neisseria gonorrhoeae and N. meningitidis are closely
related to bacteria. Although vaccines are routinely used
for N. meningitidis, there is currently no vaccine available
for N. gonorrhoeae (gonococcus). The target epitopes of
the currently licensed vaccines for meningococcus are
similarly found in gonococcus. Recent studies have proven
that N. gonorrhoeae shares a high level of sequence iden-
tity with OMV antigens in serogroup B meningococcal
vaccines, MeNZB, and 4CMenB.92–94 Antibodies in the
serum of 4CMenB vaccines are able to recognize several
gonococcal proteins, including the gonococcal NHBA
homologue.94 Theoretically, the high level of anti-gono-
coccal-NHBA antibodies generated by the MenB vaccines
may result in additional cross-protection against gonor-
rhea. It was estimated that an OMV-based vaccine has an
effectiveness estimate of 31% (95% CI 21–39) against
gonococcus.92,94
Dovepress Rivero-Calle et al
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Vaccine Coverage Of Invasive
Meningococcal Group B Isolates
To predict the strain coverage of the vaccine across differ-
ent meningococcal strains, a large panel of bacterial iso-
lates representative of invasive disease would need to be
tested for hSBA using a huge number of samples. A large
volume of serum is also needed per participant which
would pose ethical problems in pediatric studies.95
Furthermore, the SBA assay with human complement is
difficult to standardize from varying sources for different
meningococcal strains. Thus, estimation of strain coverage
of the current vaccines using conventional laboratory
methods proves cumbersome and impractical. This leads
to the development of alternative assays to measure sur-
face antigens and theoretical strain coverage of the vac-
cine. However, these novel assays are vaccine-specific as
they detect different proteins that are distinct to the vac-
cine product, thereby limiting its cross-platform utility and
comparability.
The Meningococcal Antigen Typing System (MATS)
assess if strain expressed antigens are recognized by the
vaccine-induced antibodies (basing on the variant and
quantity of expressed antigen). MATS is an ELISA test
designed specifically to measure the immunologic cross-
reactivity and quantity of antigen expression of three
4CMenB protein antigens (fHbp, NadA, and NHBA).25,96
The results are correlated with the lysis of the meningo-
coccal strains in the hSBA assays upon exceeding the
positive bacterial threshold (PBT) for any one of the 3
antigens of the vaccine with ≥80% chance of being neu-
tralized in a serum of the immunized person. Those strains
that are positive for 2 or more antigens are more likely to
be neutralized at 96%.25,96
The theoretical strain coverage of the vaccine could be
defined as the proportion of circulating strains in a given
country or region with scores (RP: relative potency) above
the bactericidal threshold (PBT) for at least one of the
three antigens. MATS has estimated strain coverage in
different countries for 4CMenB vaccine which ranges
from 66% in Canada (95% CI, 43–78%) to 91% in the
US (95% CI, 72–96%).97,98 In a study conducted using
1052 strains of MenB from 5 European countries
(Germany, France, UK, Italy, and Norway), MATS pre-
dicted that 4CmenB strain coverage would range from
73% (95% CI, 57–87%) in the UK to 87% (95% CI, 70–
93%) in Italy.45 MATS coverage increases with age, varies
by geographical region, and is associated with more severe
disease.46 Temporal changes in circulating strains under-
score the need for continued monitoring of antigen expres-
sion and diversity, particularly in countries using 4CMenB
vaccines in their respective immunization programmes.46
The Meningococcal Antigen Surface Expression
(MEASURE, Pfizer Inc.) assay was developed to assess
surface expression levels of fHbp on meningococcal
strains and prediction of complement-mediated killing by
hSBA in an immunized serum. MEASURE assesses level
of expressed antigen regardless of if the antigen is or not
recognized by the vaccine-induced antibodies. MEASURE
is a flow cytometry platform that uses a monoclonal anti-
body specific to an epitope common to both fHBP var-
iants, thereby allowing a phenotypic assessment of
expression and quantification of surface-expression on
meningococcus strains prepared via hSBA assay. Unlike
some other meningococcal epidemiologic markers, fHBP
surface expression levels determined by the flow cyto-
metric-based MEASURE assay were predictive of strain
susceptibility in the hSBA assay.99 In a large, prevalence-
based collection of invasive MenB isolates from national
reference laboratories in the United States and Europe,
95.8% of them demonstrated fHBP expression levels
greater than the limit of detection of the assay.26,60
Safety Of Meningococcal B Vaccines
4cMenB Vaccine
Some commonly observed vaccine-induced reactions have
been reported when administering 4CMenB in both
adolescents37 and infants.47 The most frequent among
adolescents and adults were pain at the injection site37
while injection-site tenderness, erythema, and fever
>38.5ºC were more frequently observed in infants (espe-
cially when 4CMenB was concomitantly administered
with routine immunization).47,100 This reactogenicity can
be prevented with the prophylactic use paracetamol pro-
vided with the vaccine without interferences in the
immunogenicity.47 For this reason, UK Joint Committee
on Vaccination and Immunisation advised the use of para-
cetamol when 4CmenB is administered to infants conco-
mitantly with other routine vaccines.47
Two large observational cohort studies investigated the
national MenB immunization programmes for infants (2–4
months) in the UK101 and in individuals (2 months to 20
years) in Quebec.102,103 After the administration of 3 mil-
lion doses of 4CMenB in the UK, 366 (41%) reports were
received related to local reactions and 364 (40%) related to
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fever.104 To note, 160 reported of a persistent nodule at the
site of injection, three (<1%) reported of Kawasaki dis-
ease, and another three reported (<1%) of sudden infant
death syndrome.104 There were no significant safety
concerns.104 On the other hand, among approximately
43,000 vaccinated individuals at Quebec, only two possi-
bly vaccine-related serious adverse events (bronchospasm)
were reported. However, the reported prevalence of local
pain (97%) and fever (44%) was high.103,105
Healthcare-associated costs of vaccine-related adverse
events or increased reactogenicity might be eventually sig-
nificant. However, its low incidence in real-life practice and
the protection the vaccine confers against the disease over-
whelmingly outweigh the risks.106 Vaccine reactogenicity
could potentially raise concerns in the immunization cam-
paigns, but accumulated experience shows that it has not had
a significant impact on the immunization program.107
rLP2086 Vaccine
Safety and immunogenicity of the vaccine were established in
several clinical trials (see Table 4).31–33,72 Localized reacto-
genicity was mainly observed in adolescent trials. Only few
systemic reactions, such as fever or headache, were attributed
to the vaccine.84,108,109 rLP2086 appears to be well tolerated in
younger children. Fever occurred in 0–40.9% of toddlers
receiving any rLP2086 vaccine dose, but was mostly mild or
moderate in severity.110 By comparison, 9.7–18.8% of parti-
cipants receiving HAV reported some fever.110 Four cases of
fever >40.0°C were reported (3 in the 200 μg group and 1 in
the 60 μg group), each of which lasted for 1 to 2 days.110
Post-marketing safety data of rLP2086 through the
Vaccine Adverse Event Reporting System (VAERS) ana-
lysis showed very few serious adverse events and no new
safety concerns.111 The first real-world experience to
examine adverse events of bivalent rLP2086 was at
Rhode Island (US) where more than 90% of a college-
age population was vaccinated.112 The most commonly
reported adverse event was injection site pain, followed
by fatigue, myalgia, and fever, similar to those reported in
clinical trials, while headache rates were lower than pre-
viously reported.112
Potential For Herd Immunity
Through The Impact On Carriage
Adolescents have the highest rates of meningococcal car-
riage and transmission rates.11 Interrupting carriage acquisi-
tion of invasive MenB strains in adolescents is crucial in the
control of meningococcal disease by reducing the transmis-
sion to other age groups through herd immunity.4,24 A
strategy focused on adolescents may have more profound
and long-lasting indirect impact, and may be more cost-
effective. Furthermore, the increasing focus of different
countries in improving adolescent health can be used as a
platform to include newer vaccines in the routine immuni-
zation program targeting this age-group. However, limited
data exist on the impact of both MenB vaccines on menin-
gococcal carriage and herd protection.113
A clinical trial evaluated meningococcal carriage among
university students in England after MenACWYor 4CMenB
vaccination. It revealed reduction in carriage observed after 3
months of the second vaccine dose.36 Another study which
evaluated carriage in high school students in the US after
MenACWY immunization concluded that carriage rates
were lower than expected, with nongroupable strains
accounting for almost 90% of isolates.36 In contrast, another
study assessed meningococcal carriage after MenB vaccina-
tion in response to a university outbreak in 2015.114 Total
MenB carriage prevalence among sampled students was
stable with eradication of the outbreak strain.114 Neither 1–
3 doses of rLP2086 nor 1–2 doses of 4CMenB were asso-
ciated with decreased total or MenB carriage prevalence and
are unlikely to provide herd protection in the context of an
outbreak response.114
Three studies evaluated MenB carriage in university
students after vaccination with MenB OMV in France115
and in the US using rLP208614 or 4CMenB.36 Only one
individual vaccinated with MenB OMV was a carrier (ser-
ogroup not determined), whereas 16 children in the unvac-
cinated group were carriers (5 carried MenB).13,14,36,114–116
Four percent (n=31) of the university students immunized
with rLP2086 were carriers of MenB at baseline. Those
receiving 4CMenB had lower carriage prevalence, that is,
only at 3 months after the second vaccine dose, and applied
to capsular groups B, C, W, and Y, rather than solely to
group B.14,36,114,115 Current evidence on disease prevention
is still inconclusive owing to the small number of cases.
To provide more evidence on the effects on meningo-
coccal carriage and prospects on generating herd immu-
nity, a cluster-randomized controlled trial enrolled 24,269
school students ≥14 years of age which used 4CMenB
(ACTRN12617000079347 and NCT03089086).117,118
Preliminary results showed that among the enrolled
patients with nasopharyngeal carriage, vaccination did
not reduce disease causing meningococcus serogroup,
including MenB.119 Similarly, no reduction was seen
Dovepress Rivero-Calle et al
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among non-groupable meningococcus carriage.119 As
such, the 4CMenB was hypothesized to have no indirect
effect.
Another meningococcal carriage trial, led by the
Oxford Vaccine Group at the University of Oxford, is
ongoing using two licensed MenB vaccines on teenagers
16–18 years old (EUDRACT 2017-004609-42).120 One
group will receive 4CMenB while another will receive
rLP2086. The vaccines will be given at the beginning of
the study and after six months. Two throat swabs will be
taken 12 months apart. A further control group will receive
4CMenB vaccine 12 months into the study. The trial will
be recruiting students in the UK for 18 months which
started in April 2018. Both studies will hopefully provide
a better understanding of the effects of the vaccines on the
nasopharyngeal carriage in adolescents.
Real-World Experience On
Vaccination Against Meningococcal B
Both 4CMenB and rLP2086 vaccines have gained market-
ing approval in several countries. 4CMenB is approved for
use in 39 countries including EU/EEA countries, Australia,
Canada, Chile, Colombia, Uruguay, and the US, and has
been included in the immunization calendar in Austria,
Czech Republic, Andorra, Lithuania, UK, Ireland, Italy,
Australia, Canada, and the US.26,121 rLP2086 is approved
for use in EU/EEA and the US in individuals 10 years of
age and older. We summarized in Table 5 the experiences of
the US, the UK, Canada, and Spain on the use of the MenB
vaccines in a public health setting.
Experience In A Nationwide Routine
Infant Immunization (UK)
4CMenB was first licensed in Europe in 2013122 and was
included in the UK’s immunization program as part of the
routine infant schedule in September 2015.123 During this
immunization program, the vaccine was administered to
infants as a reduced 2-dose primary series at 2 and 4
months of age with a booster dose at 12 months, alongside
their routine immunizations. The resulting coverage in
eligible infants was 95.5% for the first dose and 88.6%
for the second dose in the primary series.101 Catch-up
vaccination was offered to infants attending their routine
immunization at 3 months of age with 2 primary doses at 3
and 4 months (coverage was 88.8% and 75.2%, respec-
tively), or at 4 months of age with a single dose (coverage
was 76.6%).101
The vaccine effectiveness of the 2-dose primary series
was 82.9% against all Men B cases during the first 10
months of the program. Compared with the pre-vaccine
period, there was a 50% reduction of the incidence rate
ratio of Men B cases among the vaccine-eligible cohort for
4CMenB vaccine, as against a non-significant 14% reduc-
tion in the unvaccinated cohort.101
During the surveillance period from September 1, 2015
until May 31, 2017, approximately 1.29 million children
aged between 2 and 18 months received more than 3
million doses of 4CMenB vaccine. Nine hundred two
(902) reports of suspected adverse events were collected
from the UK Yellow Card Scheme, of which 366 (41%)
were related to local reactions and 364 (40%) related to
fever.104 There were no safety signals related to pre-spe-
cified adverse events of interests as the occurrence of these
events was similar to background rates.104 There was no
indication of reduced compliance with doses of other
routine vaccinations. This study is the most comprehensive
assessment of 4CMenB vaccine’s safety to date.
Experience In A Selective (US) And
Subnational Immunization
In the US, outbreaks ofMenB disease occur at universities and
other organizations. However, until October 2014, there were
no licensed MenB vaccines available for outbreak control. A
MenB disease outbreak occurred in 2013–2014 among per-
sons linked to a university in New Jersey.13 This prompted the
US Food and Drug Administration to authorize the use of an
investigational MenB vaccine to control the outbreak.124 The
attack rate among undergraduate students was 134 cases/
100,000 and was more than 1400 times greater than the
national incidence in this age group. Since cases occurred
among students of four undergraduate class years, the entire
undergraduate population was targeted for vaccination. Over
5000 students received the first-dose of 4CMenB during the
vaccination campaign, achieving 89.1% coverage with the
two-dose vaccination series. No MenB cases were reported
in vaccinated population regardless of the number of doses
administered. However, the rarity of the case precluded the
estimation of vaccine effectiveness.
In Canada, to address the high incidence serogroup B, the
Saguenay-Lac-Saint-Jean region in Quebec conducted a mass
vaccination campaign on individuals ≤20 years old from May
2014 to July 2015.124,103 4CMenB vaccinewas given targeting
59,098 individuals, achieving 83% coverage for 1 dose. For
the vaccine target age group (0–20 years old), the disease
Rivero-Calle et al Dovepress
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incidence declined by 96% from 11.4 to 0.4 cases/100,000.
For non-vaccine targets (>21 years), disease incidence
declined by 56% from 1.1 to 0.5 cases/100,000.125
Furthermore, vaccine safety surveillance reports demonstrated
an acceptable safety and risk-benefit profile in a large-scale,
population-based study.103
While the number of sporadic cases of MenB disease
occurring in each year in both the US and Canada was highly
varied, the potential impact of MenB vaccines on both spora-
dic disease and outbreaks is an important consideration in the
development of recommendations for the use of licensed
MenB vaccines.
Experience In A Limited Release Of The
Vaccine For Private Market Use In Spain
The official meniningococal B vaccine recommendation in
Spain since 2013 is limited for use in high-risk population126
However, the Spanish Pediatric Association recommends
universal vaccination of all infants with this vaccine127 As
a result, moderate immunization coverages were achieved as
vaccines were only made available in the private market
without reimbursements from the national government.128
Based on the data by the Spanish Health Ministry on the
utilization of 4CMenB in private setting, 33.55% of the infants
(2015–2016 birth cohorts) received at least 2 doses of the
vaccine129 Older birth cohorts obtained 19.2% (207–2015)
and 6.85% (2003–2006) coverage rates. The highest coverage
rate was seen in Galicia and Castilla y Leon region with
58.92% and 54.61% in the youngest birth cohort, respectively.
Since the vaccine was not included in the routine immuniza-
tion program, children may have obtained the vaccine with
varying schedules. Vaccine supply was also inconsistent
across the observation period.
To estimate the vaccine impact in Spain, the decrease
in the number of cases was roughly compared from pre-
vaccination period (2013 to 2014 period) to subsequent
post-vaccination period (2015-onwards). A decline in
cases was observed at 41.7% for 0–5 months and 65.4%
for 6–11 months comparing 2013–2014 season (baseline,
prior to immunization) and 2017–2018 season (after lim-
ited immunization in private market).129,130 There are
ongoing efforts to assess effectiveness of the 4CMenB
vaccine in Spain using a case–control design.
Conclusion
The global burden of invasive meningococcal disease remains
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most cases occur in otherwise healthy subjects, the most
effective strategy in the fight against meningococcal disease
is prevention through immunization. The immunogenicity,
effectiveness, and safety profiles of 4CMenB and rLP2086
have been demonstrated in clinical trials and population-
based surveillance studies. Available data indicate that new
MenB vaccines have the potential to have a huge impact on
the global burden of meningococcal disease. Real-world
evidence, although limited, is rapidly accumulating and is
encouraging. Post-licensure safety data are reassuring for
both vaccines. The preliminary effectiveness assessment
for 4CMenB in the UK, Canda, or Spain, looks positively
promising. Likewise, as with any new vaccine, we still have
knowledge gaps on the ideal age groups to be immunized,
the long-term duration of clinical efficacy, or the impact on
the nasopharyngeal carriage and eventual herd effect.
Universal vaccination programs such as those undertaken
in the United Kingdom will provide crucial information in
this regard. Furthermore, the potential for MenB vaccines to
prevent infection by non-B serogroups appears promising,
and the impact on other pathogenic Neisserial species with
homologous surface proteins warrants further investigation.
Overall, with the remaining burden of invasive meningo-
coccal disease across Europe and other parts of the world,
mostly of serogroup B meningococcus, new vaccines should
highly be considered for broad use.
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